Guidance

MenB vaccine (Bexsero®) offer Autumn 2026: PGD template

Patient group direction (PGD) template to support the national meningococcal group B (Bexsero®) vaccination one-off, time-limited offer Autumn 2026 programme.

• From: UK Health Security Agency
• Published: 25 June 2026

Applies to England

Documents

MenB vaccine (Bexsero®): one-off, time-limited offer Autumn 2026 patient group direction template

Ref: GOV-21250

MS Word Document, 178 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Following the unprecedented MenB outbreak primarily among University of Kent students in March 2026, and Weymouth and Reading clusters more recently, the patient group direction (PGD) is to support the administration of MenB vaccine for a one-off, time-limited, targeted vaccination programme (see Bipartite letter).

MenB vaccine PGD version 1.0 is valid from 24 June 2026 to 31 March 2027.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy and procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.

Published 25 June 2026